Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Berry Genomics Co.,Ltd, a genomics and life science company, develops and commercializes of genetic test technologies in clinical applications in China. The company offers non-invasive DNA prenatal testing service, genetic disease testing, tumor genetic testing, NextSeq CN500 gene sequencer, and laboratory solutions. It also provides technology services, such as human genome sequencing, transcriptional regulation, single cell/spatial sequencing, animal and plant genome resequencing, genome denovo sequencing, and microbial sequencing, as well as big data services. The company serves various organizations and facilities, including hospitals, research institutions, universities, and enterprises throughout Mainland China, Hong Kong, Macao, Taiwan, Southeast Asia, the Middle East, and Australia. The company was founded in 2010 and is headquartered in Beijing, China.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers.